Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.56 |
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750439 | 0.90 | TLR8 (0.56) | TLR8TLR7NUDT1 | |
| SCHEMBL14592801 | 0.89 | TLR7 (0.56) | TLR8TLR7NUDT1 | |
| SCHEMBL3924482 | 0.86 | TLR8 (0.64) | TLR8TLR7NUDT1 | |
| SCHEMBL29507644 | 0.84 | TLR8 (0.62) | TLR8TLR7NUDT1 | |
| SCHEMBL5394078 | 0.84 | TLR8 (0.62) | TLR8TLR7NUDT1 | |
| SCHEMBL5349680 | 0.83 | TLR7 (0.53) | TLR7 | |
| SCHEMBL21632208 | 0.81 | TLR8 (0.67) | TLR8TLR7NUDT1 | |
| SCHEMBL18588112 | 0.81 | TLR8 (0.66) | TLR8TLR7NUDT1 | |
| SCHEMBL7249970 | 0.80 | TLR8 (0.58) | TLR8TLR7NUDT1 | |
| SCHEMBL7253813 | 0.80 | TLR8 (0.65) | TLR8TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1198232-B1 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-23 | — | — | EP | claimed |
| US-6780873-B2 | FOR INDUCING CYTOKINE BIOSYNTHESIS IN ANIMALS, AND IN THE TREATMENT OF DISEASES, INCLUDING VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-24 | — | — | US | claimed |
| US-20040014754-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014754-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR8 237/4885TLR7 35/4885NUDT1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.